Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 307

1.
2.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Lancet Oncol. 2018 Oct 18. pii: S1470-2045(18)30686-7. doi: 10.1016/S1470-2045(18)30686-7. [Epub ahead of print]

PMID:
30348537
3.

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

Crombag MBS, van Nuland M, Bergman AM, Rosing H, Schellens JHM, Huitema ADR, Beijnen JH.

Prostate Cancer Prostatic Dis. 2018 Oct 2. doi: 10.1038/s41391-018-0096-z. [Epub ahead of print]

PMID:
30279580
4.

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?

Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR.

Br J Clin Pharmacol. 2018 Aug 1. doi: 10.1111/bcp.13725. [Epub ahead of print]

PMID:
30068020
5.

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.

Henricks LM, Jacobs BAW, Meulendijks D, Pluim D, van den Broek D, de Vries N, Rosing H, Beijnen JH, Huitema ADR, Guchelaar HJ, Cats A, Schellens JHM.

Br J Clin Pharmacol. 2018 Jul 26. doi: 10.1111/bcp.13719. [Epub ahead of print]

PMID:
30047584
6.

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment.

van Andel L, Rosing H, Schellens JH, Beijnen JH.

Mar Drugs. 2018 Jul 23;16(7). pii: E246. doi: 10.3390/md16070246. Review.

7.

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.

van Nuland M, Vreman RA, Ten Ham RMT, de Vries Schultink AHM, Rosing H, Schellens JHM, Beijnen JH, Hövels AM.

Breast Cancer Res Treat. 2018 Jul 13. doi: 10.1007/s10549-018-4886-8. [Epub ahead of print]

8.

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin.

van Andel L, Rosing H, Tibben MM, Lucas L, Lubomirov R, Avilés P, Francesch A, Fudio S, Gebretensae A, Hillebrand MJX, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Sep;82(3):441-455. doi: 10.1007/s00280-018-3637-1. Epub 2018 Jul 4.

PMID:
29974200
9.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.

van Andel L, Rosing H, Lubomirov R, Avilés P, Fudio S, Tibben MM, Nan-Offeringa L, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Sep 5;158:160-165. doi: 10.1016/j.jpba.2018.05.053. Epub 2018 Jun 1.

PMID:
29883879
10.

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.

Derissen EJB, Huitema ADR, Rosing H, Schellens JHM, Beijnen JH.

Br J Clin Pharmacol. 2018 Jun;84(6):1279-1289. doi: 10.1111/bcp.13557. Epub 2018 Apr 16.

PMID:
29451684
11.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.

Jacobs BAW, Snoeren N, Samim M, Rosing H, de Vries N, Deenen MJ, Beijnen JH, Schellens JHM, Koopman M, van Hillegersberg R.

Eur J Clin Pharmacol. 2018 Jun;74(6):737-744. doi: 10.1007/s00228-018-2426-4. Epub 2018 Feb 11.

PMID:
29430582
12.

Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial.

van Nuland M, Hillebrand MJX, Rosing H, Burgers JA, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Mar 20;151:25-31. doi: 10.1016/j.jpba.2017.12.048. Epub 2017 Dec 26.

PMID:
29294409
13.

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.

Verheijen RB, Thijssen B, Rosing H, Schellens JHM, Nan L, Venekamp N, Beijnen JH, Steeghs N, Huitema ADR.

Ther Drug Monit. 2018 Apr;40(2):230-236. doi: 10.1097/FTD.0000000000000479.

PMID:
29256969
14.

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Jan;81(1):47. doi: 10.1007/s00280-017-3474-7.

15.

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

Herbrink M, de Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM, Beijnen JH.

Biomed Chromatogr. 2018 Apr;32(4). doi: 10.1002/bmc.4147. Epub 2017 Dec 19.

PMID:
29165815
16.

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma.

Herbrink M, Thijssen B, Hillebrand MJX, Rosing H, Schellens JHM, Nuijen B, Beijnen JH.

J Pharm Biomed Anal. 2018 Jan 30;148:259-264. doi: 10.1016/j.jpba.2017.10.009. Epub 2017 Oct 18.

PMID:
29059615
17.

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.

van Nuland M, Rosing H, de Vries J, Ovaa H, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Nov 15;1068-1069:119-124. doi: 10.1016/j.jchromb.2017.10.033. Epub 2017 Oct 16.

PMID:
29059586
18.

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Jan;81(1):39-46. doi: 10.1007/s00280-017-3455-x. Epub 2017 Oct 17. Erratum in: Cancer Chemother Pharmacol. 2017 Nov 27;:.

19.

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

de Weger VA, Stuurman FE, Hendrikx JJMA, Moes JJ, Sawicki E, Huitema ADR, Nuijen B, Thijssen B, Rosing H, Keessen M, Mergui-Roelvink M, Beijnen JH, Schellens JHM, Marchetti S.

Eur J Cancer. 2017 Nov;86:217-225. doi: 10.1016/j.ejca.2017.09.010. Epub 2017 Oct 12.

PMID:
29031170
20.

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.

de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB.

Oncotarget. 2017 Jun 15;8(37):60750-60763. doi: 10.18632/oncotarget.18490. eCollection 2017 Sep 22.

21.

Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.

Henricks LM, Siemerink EJM, Rosing H, Meijer J, Goorden SMI, Polstra AM, Zoetekouw L, Cats A, Schellens JHM, van Kuilenburg ABP.

Int J Cancer. 2018 Jan 15;142(2):424-430. doi: 10.1002/ijc.31065. Epub 2017 Sep 30.

PMID:
28929491
22.

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.

Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L.

Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4.

23.

Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine.

van Andel L, Rosing H, Fudio S, Avilés P, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2017 Oct 25;145:137-143. doi: 10.1016/j.jpba.2017.06.013. Epub 2017 Jun 21.

PMID:
28662481
24.

Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma.

van Nuland M, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH.

Ther Drug Monit. 2017 Jun;39(3):243-251. doi: 10.1097/FTD.0000000000000387.

PMID:
28490047
25.

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.

Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, Rosing H, van Werkhoven E, de Boer A, Beijnen JH, Mandigers CMPW, Soesan M, Cats A, Schellens JHM.

Br J Cancer. 2017 May 23;116(11):1415-1424. doi: 10.1038/bjc.2017.94. Epub 2017 Apr 20.

26.

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.

van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Lucas L, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH.

Invest New Drugs. 2017 Dec;35(6):751-765. doi: 10.1007/s10637-017-0451-2. Epub 2017 Mar 16.

27.

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.

Nijenhuis CM, Lucas L, Rosing H, Huitema ADR, Mergui-Roelvink M, Jamieson GC, Fox JA, Mould DR, Schellens JHM, Beijnen JH.

Invest New Drugs. 2017 Aug;35(4):478-490. doi: 10.1007/s10637-017-0428-1. Epub 2017 Jan 31.

PMID:
28138829
28.

Pharmacokinetics and excretion of 14C-Plitidepsin in patients with advanced cancer.

van Andel L, Fudio S, Rosing H, Munt S, Miguel-Lillo B, González I, Tibben MM, de Vries N, de Vries Schultink AHM, Schellens JHM, Beijnen JH.

Invest New Drugs. 2017 Oct;35(5):589-598. doi: 10.1007/s10637-017-0432-5. Epub 2017 Jan 23.

PMID:
28111728
29.

Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.

de Krou S, Rosing H, Nuijen B, Schellens JH, Beijnen JH.

Ther Drug Monit. 2017 Apr;39(2):132-137. doi: 10.1097/FTD.0000000000000372.

PMID:
28045782
30.

Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples.

Kip AE, Kiers KC, Rosing H, Schellens JHM, Beijnen JH, Dorlo TPC.

J Pharm Biomed Anal. 2017 Feb 20;135:160-166. doi: 10.1016/j.jpba.2016.12.012. Epub 2016 Dec 9.

PMID:
28033553
31.

Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.

van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Rosing H, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 1;1040:14-21. doi: 10.1016/j.jchromb.2016.11.020. Epub 2016 Nov 19.

PMID:
27898364
32.

Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.

Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, Beijnen JH.

Ther Drug Monit. 2016 Dec;38(6):649-656.

PMID:
27749781
33.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.

Sparidans RW, Rosing H, Rood JJM, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:390-398. doi: 10.1016/j.jchromb.2016.09.012. Epub 2016 Sep 11. No abstract available.

PMID:
27639128
34.

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar.

Sawicki E, Hillebrand MJ, Rosing H, Schellens JHM, Nuijen B, Beijnen JH.

J Pharm Anal. 2016 Aug;6(4):268-275. doi: 10.1016/j.jpha.2016.04.005. Epub 2016 Apr 23.

35.

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

Nijenhuis CM, Huitema AD, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH.

J Clin Pharmacol. 2017 Jan;57(1):125-128. doi: 10.1002/jcph.788. Epub 2016 Jul 29. No abstract available.

PMID:
27365214
36.

Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis.

Krashin E, Dolberg OJ, Hellmann I, Huitema AD, Rosing H, Ellis M.

Anticancer Drugs. 2016 Sep;27(8):800-3. doi: 10.1097/CAD.0000000000000382.

PMID:
27254285
37.

Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry.

Nijenhuis CM, Lucas L, Rosing H, Jamieson G, Fox JA, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 1;1027:1-10. doi: 10.1016/j.jchromb.2016.05.016. Epub 2016 May 13.

PMID:
27236532
38.

Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors.

Nijenhuis CM, Hellriegel E, Beijnen JH, Hershock D, Huitema AD, Lucas L, Mergui-Roelvink M, Munteanu M, Rabinovich-Guilatt L, Robertson P Jr, Rosing H, Spiegelstein O, Schellens JH.

Invest New Drugs. 2016 Oct;34(5):565-74. doi: 10.1007/s10637-016-0360-9. Epub 2016 May 25.

39.

Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma.

Jacobs BA, Rosing H, de Vries N, Meulendijks D, Henricks LM, Schellens JH, Beijnen JH.

J Pharm Biomed Anal. 2016 Jul 15;126:75-82. doi: 10.1016/j.jpba.2016.04.039. Epub 2016 Apr 29.

PMID:
27179185
40.

Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, Schellens JH.

Br J Clin Pharmacol. 2016 Sep;82(3):706-16. doi: 10.1111/bcp.13007. Epub 2016 Jun 3.

41.

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.

Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, Schellens JH, Marchetti S.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1201-7. doi: 10.1007/s00280-016-3035-5. Epub 2016 Apr 21.

PMID:
27103124
42.

Corrigendum to "Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine" [J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 893-894 (2012) 92-100].

Dubbelman AC, Tibben M, Rosing H, Gebretensae A, Nan L, Gorman SH, Robertson P Jr, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 May 1;1020:168-9. doi: 10.1016/j.jchromb.2016.03.016. Epub 2016 Mar 25. No abstract available.

PMID:
27063483
43.

Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry.

Nijenhuis CM, Haverkate H, Rosing H, Schellens JH, Beijnen JH.

J Pharm Biomed Anal. 2016 Jun 5;125:270-9. doi: 10.1016/j.jpba.2016.03.049. Epub 2016 Mar 25.

PMID:
27058232
44.

Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison.

Dubbelman AC, Nijenhuis CM, Jansen RS, Rosing H, Mizuo H, Kawaguchi S, Critchley D, Shumaker R, Schellens JH, Beijnen JH.

Invest New Drugs. 2016 Jun;34(3):300-18. doi: 10.1007/s10637-016-0342-y. Epub 2016 Mar 28.

PMID:
27018262
45.

Metabolite profiling of 14C-omacetaxine mepesuccinate in plasma and excreta of cancer patients.

Nijenhuis CM, Lucas L, Rosing H, Robertson P Jr, Hellriegel ET, Schellens JH, Beijnen AJ.

Xenobiotica. 2016 Dec;46(12):1122-1132. Epub 2016 Mar 21.

PMID:
26998885
46.

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.

Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH.

J Clin Pharmacol. 2016 Oct;56(10):1307-12. doi: 10.1002/jcph.728. Epub 2016 Apr 8.

PMID:
26918324
47.

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.

Kip AE, Rosing H, Hillebrand MJ, Blesson S, Mengesha B, Diro E, Hailu A, Schellens JH, Beijnen JH, Dorlo TP.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2081-9. doi: 10.1128/AAC.02976-15. Print 2016 Apr.

48.

Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.

Derissen EJ, Jacobs BA, Huitema AD, Rosing H, Schellens JH, Beijnen JH.

Br J Clin Pharmacol. 2016 May;81(5):949-57. doi: 10.1111/bcp.12877. Epub 2016 Mar 2.

49.

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).

Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, Overkleeft HS, Sessa C, Huitema A, Pabst T, von Moos R, Hess D, Mey UJ.

Haematologica. 2016 Mar;101(3):346-55. doi: 10.3324/haematol.2015.135780. Epub 2015 Dec 11.

50.

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD.

Bioanalysis. 2016;8(2):123-34. doi: 10.4155/bio.15.235. Epub 2015 Dec 10.

PMID:
26652864

Supplemental Content

Loading ...
Support Center